糖尿病视网膜病变 中国就医指南

Diabetic retinopathy (DR) is a progressive microvascular complication of diabetes mellitus and the leading cause of preventable blindness among working-age adults worldwide. It results from chronic hyperglycemia-induced damage to the retinal capillaries, leading to vascular leakage, ischemia, inflammation, and pathological neovascularization. Pathogenesis involves multiple interrelated mechanisms: persistent hyperglycemia triggers oxidative stress, advanced glycation end-product (AGE) accumulation, protein kinase C activation, and polyol pathway flux — all contributing to pericyte loss, basement membrane thickening, endothelial dysfunction, and breakdown of the blood-retinal barrier. As disease advances, non-proliferative diabetic retinopathy (NPDR) may evolve into proliferative diabetic retinopathy (PDR), characterized by fragile new vessels prone to vitreous hemorrhage and tractional retinal detachment. Epidemiologically, approximately one-third of people with diabetes have some form of DR, with prevalence rising to over 50% in those with >20 years’ duration of type 1 or type 2 diabetes. Globally, an estimated 93 million people live with DR, and nearly 3 million suffer vision-threatening stages. Key modifiable risk factors include poor glycemic control (elevated HbA1c), hypertension, dyslipidemia, duration of diabetes, pregnancy, and renal disease; non-modifiable factors include genetic susceptibility, ethnicity (higher incidence in Hispanic and African American populations), and age. Early-stage DR is typically asymptomatic, delaying diagnosis until irreversible structural damage occurs. As it progresses, patients may experience blurred or fluctuating vision, floaters, dark or empty areas in the visual field, impaired color perception, and sudden vision loss. Beyond functional impairment, DR significantly diminishes quality of life—contributing to anxiety, depression, reduced mobility, occupational limitations, social isolation, and increased caregiver burden. Timely screening via dilated fundus examination or ultra-widefield retinal imaging is critical, as early intervention can reduce severe vision loss by up to 95%. Multidisciplinary management involving endocrinologists, ophthalmologists, and primary care providers is essential for optimizing systemic control and ocular outcomes.

# 糖尿病视网膜病变治疗方案与费用明细（内分泌科协同眼科管理）

一、非手术/保守治疗（适用于NPDR早期、血糖控制不佳但无明显视力损害者）

• •基础管理：强化血糖（HbA1c＜7%）、血压（＜130/80 mmHg）、血脂达标；每3–6个月眼底照相+OCT检查

• •药物干预：羟苯磺酸钙（国产/进口）口服，疗程3–6个月

二、激光/微创介入治疗（适用于中重度NPDR或PDR初发、黄斑水肿未累及中心凹）

• •全视网膜光凝（PRP）：单眼操作，分次完成（2–3次）

• •抗VEGF玻璃体腔注射（如雷珠单抗、康柏西普）：需内分泌科评估全身风险后转介眼科执行

三、晚期/复杂并发症方案（如牵拉性视网膜脱离、难治性黄斑水肿、玻璃体积血）

• •玻璃体切除术（PPV）：单眼手术，联合内界膜剥除、硅油填充等

方案快速选择指南

• •预算有限/初筛患者：选非手术管理（年均总费用≤5,000元）
• •进展期PDR/黄斑水肿：首选抗VEGF注射（首年费用约12,000–20,000元）
• •视力骤降/结构破坏明显：及时转诊PPV（单眼总支出约2.0–3.5万元）